


38-02

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

03/07/02
J1165 U.S. PTO

BOX NEW APPLICATION
Commissioner for Patents
Washington D.C. 20231

EXPRESS MAIL MAILING LABEL	
NUMBER EL830942999 US	
DATE OF DEPOSIT : March 7, 2002	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington D.C. 20231	
 Signature	

J1046 U.S. PTO
10/092849
03/07/02

Transmitted with this paper is the patent application of:

Inventors: David D. Frisbie, Fort Collins, Colorado, U.S.A. and
C. Wayne McIlwraith, Fort Collins, Colorado, U.S.A.

Titled: IN VIVO TREATMENT OF JOINT DISEASE USING INTERLEUKIN-1 RECEPTOR
ANTAGONISTS

Attorney Docket No. 10606.0026.PCUS00 (CSUA:026)

Enclosed are:

- ☒ A specification including: 26 pages of disclosure, 3 page(s) of claims, and an Abstract.
- ☐ Drawings consisting of ___ sheets.
- ☐ Declaration and Power of Attorney.
- ☒ An assignment of the invention to Colorado State University Research Foundation, which was previously recorded at Reel 011644, Frame 0730.
- ☐ The assignee of this application is a small entity under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.
- ☒ An Information Disclosure Statement including Form 1449 and the cited references.
- ☒ Sequence Listing and Statement as Required Under 37 C.F.R. § 1.821(f).
- ☒ Additional Items: return receipt post card.
- ☒ Applicants claim the benefit of prior U.S. provisional patent application Serial No. 60/152,707, filed September 6, 1999, and prior International patent application PCT/US00/40823, filed September 6, 2000.

- ☒ Please amend the specification at page 1, line 6 to recite -- This patent application claims priority from U.S. Provisional patent application Serial No. 60/152,707, filed September 6, 1999, and International patent application PCT/US00/40823 filed September 6, 2000, each incorporated herein by reference in entirety.--

CALCULATION OF FILING FEE: The filing fee was calculated as follows:

			Fees	
Total Claims	36 - 20	= 16	x \$ 18.00	= \$ 288.00
Independent Claims	6 - 3	= 3	x \$ 84.00	= \$ 252.00
First Multiply Dependent Claim Presented			+ \$ 270.00	= \$ 0.00
Basic Fee			+ \$ 740.00	= \$ 740.00
Total Fees = \$ 1280.00				


The Commissioner is authorized to charge the above filing fee and any additional fees that may be required, or credit any overpayment, to Deposit Account No. 01-2508, Order No. 10606.0026.PCUS00. An additional copy of this sheet is enclosed for this purpose.

Please address all correspondence to:

Janelle D. Waack
HOWREY SIMON ARNOLD & WHITE LLP
750 Bering Drive
Houston, Texas 77057

Please address all telephone calls to Janelle D. Waack at 713-787-1400.

Respectfully submitted,



Janelle D. Waack
Reg. No. 36,300

Attorney for Assignee
COLORADO STATE UNIVERSITY
RESEARCH FOUNDATION

Date: March 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

DAVID D. FRISBIE
C. WAYNE MCILWRAITH

Serial No.: not yet assigned

Filed: March 7, 2002

For: IN VIVO TREATMENT OF JOINT
DISEASE USING INTERLEUKIN-1
RECEPTOR ANTAGONISTS

Group Art Unit: not yet assigned

Atty. Dkt. No.: 10606.0026.PCUS00
CSUA:026


**SEQUENCE LISTING AND
STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)**

EXPRESS MAIL MAILING LABEL

NUMBER EL830942999 US

DATE OF DEPOSIT : March 7, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington D C 20231


Signature

Commissioner for Patents
Washington DC 20231

Sir:

Enclosed is an original computer readable form and an original paper copy of the sequence listing of those sequences provided in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

Should any fees be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/10606.0026.PCUS00.

Respectfully submitted,



Janelle D. Waack
Reg. No. 36,300
Attorney for Assignee
COLORADO STATE UNIVERSITY
RESEARCH FOUNDATION

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057
713-787-1400

Date: March 7, 2002